New Data Shows Combination Therapy is More Effective than Monotherapy in ...
INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG ...
Read Full Story
Advertise Here contact ads[@]ghheadlines.com
Facebook
Twitter
Pinterest
Instagram
Google+
YouTube
LinkedIn
RSS